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ABSTRACT. Ten children with end stage renal disease on chronic hemofiltration (HF) were studied for a 1-yr period to evaluate the efficacy of 1,25-dihydroxyvitamin-D3 (1, 25 (OH)2D3) therapy on biohumoral parameters of renal osteodystrophy and bone mineral content. In six of these children an acute study was done of the direct effect of the H F procedure on calcium and phosphate balance during 12 H F sessions. During the first 6 months of the study all children were treated with 1,25(OH)zD3 (0.25-0.50 pg/ day) to maintain plasma calcium at 9.5-1 1.0 mg/dl. There was a significant increase in plasma calcium ( p < 0.05) and a significant decrease in plasma phosphate ( p < 0.01) and alkaline phosphatase concentrations ( p < 0.05). The circulating levels of NH2 immunoreactive parathyroid hormone did not change, remaining at the upper limits of reference values. Immunoreactive parathyroid hormone-COOH terminal fragment levels decreased significantly (p < 0.05). Bone mineral content rose significantly ( p < 0.01).
During the last 6 months of the study, to evaluate the possibility that H F alone might control secondary hyperparathyroidism, 1,25(OH)2D3 treatment was discontinued in five children; plasma calcium and phosphate were well controlled whereas hyperparathyroidism worsened in all five, and one also developed intense pruritus and hypertension. The other five children remained on 1,25(OH)2D3 treatment; two of these were transplanted, and the other three continued to show an improvement of mineral balance. The results of the acute study showed that calcium balance was positive with a mean Ca++ gain of 140 mg/HF session. The mean total phosphate removed per H F run was 574 mg. We conclude that even though a calcium gain and a high phosphate removal was obtained with our H F prescription, secondary hyperparathyroidism in children on chronic H F may be maintainued under control if 1, 25 There are many reports of long-term 1,25(OH)2D3 treatment of children with ESRD with and without chronic HD or chronic ambulatory peritoneal dialysis (1-7). However, there has been no study of such treatment in children on chronic HF, a replacement method based on convective transport (8) recently introduced in children (9) . This method has been reported to be more effective than HD in removing toxins of middle and large molecular weight (10) and in reducing hypotension and other symptoms of dialysis intolerance in uremic adults and children (9, 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . HF has been variously claimed to improve (l3), worsen (14) , or not change (15) hyperparathyroidism in uremic adults. Such discrepancies may be explained by differences both in vitamin D supplementation and in calcium balance during the HF procedure. The aim of the present study was to investigate the effect of 1,25(OH)2D3 treatment on the most important biohumoral parameters of renal osteodystrophy and BMC in 10 children on chronic HF. In addition, we evaluated mineral metabolism in five of these children on HF without vitamin D supplementation. Finally, an acute study was done of the effect of the HF procedure on calcium and phosphate balance during 12 HF sessions.
MATERIALS AND METHODS
Patients. Ten children (age 5.9-1 5.0 yr) with ESRD on chronic HF were prospectively studied for 1 yr after treatment by HD for a mean of 26.6 months (range 9-90 months) ( Table I ). All were anuric at the start of the study, except patient 3 who had a residual renal glomerular function below 1 ml/min. Two patients were binephrectomized 3 yr earlier because of uncontrolled hypertension. No calcium or phosphate supplementation was prescribed during the study. Systemic acidosis was corrected with oral bicarbonate therapy, both before and during the study. Reference values for plasma calcium, phosphate, and alkaline phosphatase levels were obtained from a control group of 110 normal children (age 5-15 yr). Reference values of BMC, iPTH, and vitamin D metabolites were available from 60 of the control children.
STUDY PROTOCOL
Long-Term Study. The 12-month study was divided into two periods of 6 months each as follows.
Period I. All the children, previously on HD, started HF. During the last 6 months of HD, 1 ,25(OH),D3 (0.25-5.0 pg/day) was introduced to maintain plasma calcium at 9.5-1 1.0 mg/dl. The children continued 1,25(OH)2D3 treatment during HF.
Period II. All patients remained on HF but were divided at random into subgroups of five children each. Subgroup 1 continued to take 1,25(OH)2D3; vitamin D was discontinued in subgroup 2 children. Two of the children in subgroup 1 were transplanted during this period and these children were not studied further. Patient 4 developed manifestations of severe hyperparathyroidism and was studied for an additional 3 months. Acute Study. To evaluate the effects of HF per se on mineral balance, we studied calcium and phosphate balance during an HF session twice in each of six children for a total of 12 balances. Ultrafiltrate samples consisting of the fluid obtained in 1 min were drawn every half-hour. The calcium balance was determined according to the formula:
where CasF is the substitution fluid calcium concentration (mg/ dl), IR is the fluid reinfusion rate (ml/min), CaUF is the ultrafiltrate calcium concentration (mg/dl), and UR is the ultrafiltration rate (ml/min). Blood samples were drawn at the beginning and at 1-h intervals until the end of the session. In all the samples plasma calcium and phosphate were measured. In addition we measured the hematocrit and plasma protein concentration in the first and last samples.
METHODS
HF was performed with a hollow-fiber polyamide membrane determining a mean ultrafiltration rate of 66.7 k 15.0 ml/min, with a mean blood flow of 210 f. 69 ml/min. The replacement of the substitution fluid (Na' = 140; K+ = 1.5; C1-= 105; Mg+ = 1.5; Ca++ = 4.5; lactate = 42 mEq/liter) was regulated employing a postdilutional computerized method using the gravimetric principle. HF was prescribed to maintain a pretreatment blood urea nitrogen value of 100 & 20 mg/dl by a urea kinetic model ( 16) .
Plasma iPTH was measured by radioimmunoassay using a specific chicken anti-iPTH serum directed against 1-34 human PTH (NH2 iPTH) and a second antiserum directed against 65-84 human PTH (COOH-iPTH). For both assay systems the intraassay coeficient of variation obtained in our laboratory was 3%; the interassay variation was 7-8% in accordance with data in the literature (17) . Plasma vitamin D metabolites were extracted with diethyl ether; 25-hydroxycholecalciferol and 1,25(OH)2D3 were separated and purified with three elutions in a silicic acid column. Metabolites were further characterized by high-protein liquid chromatography. 25-Hydroxycholecalciferol and 1 ,25(OH)2D3 were measured by radioimmunoassay (1 8, 19 ). Our intra-and interassay variations were 4 and 9%, respectively, for both methods.
BMC was evaluated by direct photon absorptiometry with a Gambro Bone Densitometer ('251 source) connected on-line with an Apple I1 computer. Measurements were made at midshaft of the radius and ulna of the nonfistula forearm. Roentgenograms of hands, knees, ankles, shoulders, pelvis, hips, lumbar spine, and skull were performed in all the children a month before beginning the study. Skeletal radiography was repeated at the end of the study only in the patients who showed radiological signs compatible with secondary hyperparathyroidism at the first radiography.
Data are presented as means f. SD. Data were analyzed with Student's t test for paired data for the first period of the study. For the second period only clinical observations and mean values or percentages are presented because of the small number of patients in the two subgroups.
Informed consent was obtained from patients' parents and individually from the older children. Table 2 . After 6 months of HF and 1,25(OH)2D3 treatment there was an improvement of some of the biochemical parameters considered. Plasma czlcium increased significantly ( p < 0.05). Hypercalcemia (>I 1.0 mg/dl) was observed in 1 1 of 120 measurements (9%) made during the period. Plasma phosphate levels decreased significantly ( p < 0.0 1). There were 120 plasma phosphate measurements for this period; one episode of hypophosphatemia and 17 episodes (14% of all the determinations) of hyperphosphatemia were observed (compared with reference values obtained in our normal children which differ according to age). The plasma calcium x phosphate product exceeded 60 in only 6% of determinations. The mean dose of oral aluminum hydroxide to maintain plasma phosphate in the normal range for age decreased significantly during the period (from 121 +-46 mg/kg/day at the beginning of the study to 88 k 54 mg/kg/day at month 6; p < 0.02). Mean values for plasma alkaline phosphatase and iPTH-COOH decreased significantly ( p < 0.05); mean iPTH-NH2 remained unchanged as did mean 25-hydroxyvitamin-D3 and 1,25(OH)& At the beginning of the study 4 of the 10 children studied had BMC 3 SD below the mean of our normal children of the same age and sex; another child had a BMC below 2 SD; in two it was under 1 SD, and only three children had BMC in the normal range for sex and age. BMC rose significantly in all the children during this period (radius: 383 f. 26 mg/cm2 at the beginning versus 404 f 27 mg/ cm2 at month 6; p < 0.0 1 (Fig. 1) ; ulna: 385 k 88 versus 4 17 + 82 mg/cm2; p < 0.01). The skeletal radiographic evaluations performed in all children 1 month before beginning the study were normal in all but patient 6 who had a cyst in the proximal region of one femur compatible with secondary hyperparathyroidism.
Period II. Subgroup 1. Mean plasma calcium phosphate levels (Fig. 2) and an increase in BMC (Fig. 1) . At the end of the period the skeletal radiography was repeated in patient 6; there was no change in the cyst compared with the previous roentgenogram and no other signs of secondary hyperparathyroidism. Subgroup 2. Mean plasma calcium and phosphate levels remained unchanged during the period for the five children not treated with 1,25(OH)2D3 (10.2 a 0.5 and 4.7 2 0.9 mg/dl, respectively) and also the oral aluminum hydroxide dosage was not changed. There was a slight decrease in the incidence of hypercalcemic episodes compared with period I (from 9 to 6%) and the plasma calcium x phosphate product exceeded 60 in only 3% of the determinations. Despite the adequate plasma calcium and phosphate control mean plasma alkaline phosphatase and both COOH and NH2 iPTH increased in all the children (Fig. 2) ; BMC did not change (Fig. I) . One child of this group (patient 4) developed intense pruritus and hypertension after discontinuing 1,25(OH)2D3 supplementation. His plasma calcium and phosphate remained between 9.5 and 1 1.0 mg/dl during the period but plasma alkaline phosphatase increased from 44 to 160 Ulliter (reference values in our control group 20-48 Ulliter). Both NH2 and COOH terminal fragments of iPTH greatly increased: iPTH-COOH from 1,300 to 10,980 pg/ml (reference values under 500 pglml) and iPTH- ALK. PHosPHATASE % ' " 1 NH2 from 90 to 953 pg/ml (reference values under 200 pg/ml). His hypertension was moderate (mean value of all the determinations obtained prior to each HF session 150/100) and an antihypertensive drug (hydralazine 3 mg/kg/day) was prescribed. One month after the reintroduction of 1,25(OH)2D3 therapy at a dose of 0.50 pg/day plasma calcium increased from 10.0 to 10.5 mgldl, plasma phosphate decreased from 5.4 to 4.9 mg/dl, and plasma alkaline phosphatase fell from 160 to 90 U/l. There was a decrease in both iPTH-COOH (3600 pg/ml) and iPTH-NH2 (300 pglml). Blood pressure returned to normal (130184) and the antihypertensive drug was discontinued.
Acute study. Total calcium balance in the 12 studies was positive with a total calcium gain per HF session of 139.8 k 37.0 mg ( Table 3 ). The total phosphate removed was estimated to be 573.8 +-70.0 mg per HF session. Plasma total calcium significantly increased at the end of the session compared with the beginning while there was a significant decrease in plasma phosphate (from 4.6 k 0.9 to 1.9 f 0.4 mg/dl; p < 0.001) ( Table 3) .
No significant change was observed in plasma total protein concentration and hematocrit.
DISCUSSION
The present results in children with ESRD treated with 1,25(OH)2D3 and HF showed that the biohumoral parameters of mineral metabolism and BMC were well controlled. Although we cannot compare the effect of 1 ,25(OH)2D3 in HD and HF, it appears that the administration of this drug to children on chronic HF may control renal osteodystrophy as well as during HD. Partial suppression of the hypocalcemic and hyperphosphatemic stimuli (21) (22) (23) and probably the direct action of 1,25(OH)2D3 on the parathyroid gland (23, 24) account for the control of iPTH during the study. During the first 6 months of HF and 1,25(OH)2D3 the significant decrease in mean plasma phosphate concentration associated with a decreased oral aluminum hydroxide requirement cannot be explained by the direct effect of 1,25(OH)2D3 therapy. In fact it is well known that 1,25(OH)2D3 increases intestinal absorption of phosphorus and phosphatemia (24) . Probably the decrease in plasma phosphate level was due both to the increase in plasma calcium levels and the high rate of phosphate removal obtained with our HF prescription (with a mean of 574 mg of phosphate removed during an HF run).
Also we studied the effect of HF on mineral balance without 1 ,25(OH)2D3 therapy. Results during 12 acute studies indicated that we obtained a positive calcium balance with a mean calcium gain of 140 mg during an HF session. This is in accordance with findings reported in studies of adults using HF infusion bags with a high calcium content (Ca++ > 8.0 mg/dl) (26, 27) . This result associated with the high phosphate removal obtained with our HF prescription suggests an improvement of secondary hyperparathyroidism in these patients. However, during our long-term study in all five of the subgroup 2 children, hyperparathyroidism worsened and BMC decreased despite good~cal~um-phosphate control. In contrast, hyperparathyroidism in the three patients who continued 1,25(OH)2D3 treatment improved further during the second study period. The key role of 1,25(OH)2D3 supplementation in these children is supported by the worsening hyperparathyroidism observed in patient 4 during the second study period accompanied by the development of pruritus and hypertension when vitamin D supplementation was discontinued; these changes were promptly reversed by the reintroduction of 1,25(OH)2D3.
In conclusion, our study indicates that renal osteodystrophy is not controlled by HF alone. 1,25(OH)*D3 supplementation is necessary to normalize the biohumoral parameters of calcium and phosphate metabolism and improve BMC.
